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Primer
Introduction
African trypanosomes, such as Trypanosoma brucei, are 
protistan parasites that cause sleeping sickness. Though first 
described more than a century ago, trypanosomes remain 
a blight on the health of the human population and on 
the economy of sub-Saharan Africa. T. brucei replicates in 
the bloodstream of infected mammals and traverses the 
blood-brain barrier to enter the central nervous system in 
the late, frequently fatal, stages of the disease.  Because of 
its extracellular lifestyle, T. brucei is continuously exposed 
to antibody challenge. To circumvent this, the parasite uses 
antigenic variation of a surface protein named the variant 
surface glycoprotein (VSG). Around 107 VSG molecules are 
expressed on the parasite’s cell surface, creating a dense 
coat that prevents adaptive immunity from detecting or 
accessing invariant antigens. However, antibodies against the 
expressed VSG are generated, and periodic switches to an 
immunologically distinct VSG coat are necessary for parasite 
survival. Such switches are pre-emptive of the immune 
response and contribute to the pattern of trypanosome 
growth seen in an infected host (Figure 1): parasite numbers 
increase, but then drop as VSG-specific antibodies are raised 
by the host. Cells that have switched to another VSG coat 
survive this killing and seed the outgrowth of a subsequent 
peak of parasites, which is again decimated by anti-VSG 
immune killing. As a survival strategy, antigenic variation 
succeeds by prolonging the time that the parasite resides 
in the host, thereby enhancing transmission to a new host, 
which occurs via the tsetse fly (Glossina spp.) vector. The 
nature of VSG switching (see below) suggests that antigenic 
variation has another goal: to allow trypanosomes to infect 
new hosts that already have immunity to some VSGs as a 
result of previous infections [1]. 
Antigenic variation is a widely used strategy for immune 
evasion [2] that has three common requirements in nonviral 
pathogens [3]. First, a family of genes encoding antigenically 
distinct surface antigens is needed. The T. brucei genome 
contains >1,000 VSG genes [4], dwarfing the number of 
variant antigen genes found in other organisms. For instance, 
antigenic variation in Plasmodium falciparum, the causative 
agent of human malaria, uses 60 var genes, which encode 
P. falciparum erythrocyte membrane protein 1 (PfEMP1). 
Similar antigen gene numbers are found in some bacteria, 
such as Borrelia hermsii, while other bacteria operate with 
substantially fewer numbers. Anaplasma marginale appears to 
have a particular paucity: here, antigenic variation succeeds 
with as few as five distinct Major Surface Protein 2 (MSP2) 
genes [5]. Second, a single pathogen cell must express 
one variant antigen gene at a time, to avoid exhausting the 
surface antigen repertoire. Finally, a mechanism is needed 
to switch the single expressed antigen gene. Two strategies 
have evolved to meet these requirements. In some pathogens, 
including P. falciparum and Giardia lamblia, antigen switching 
occurs by purely transcriptional mechanisms that are not 
associated with DNA rearrangements. In this strategy, a single 
antigen gene is expressed, but periodically that expression 
is silenced and a second gene activated. The other route 
for switching, such as in A. marginale or Neisseria spp., is 
based on recombination. Here, singular expression relies 
on the presence of a site for antigen gene expression, and 
switching to new variants is achieved by recombination 
into the expression site. In fact, most such recombination 
appears to be driven by gene conversion [5], where a silent 
antigen gene (or part of a gene) is copied and duplicated 
into the expression site, deleting the resident gene. Antigenic 
variation in T. brucei appears remarkable (though not unique) 
in that it uses both strategies, perhaps side-by-side (Figures 1 
and 2).
The huge VSG family of T. brucei is found primarily in 
subtelomeric gene arrays in the 11 diploid megabase-
sized chromosomes of the parasite [4]. T. brucei also has 
intermediate and mini chromosomes, which number around 
1–10 and 100, respectively, and which harbour further VSGs 
at the telomeres. Most VSGs in the subtelomeric arrays 
are pseudogenes, but nevertheless contribute to antigenic 
variation [4]. Activation of individual VSGs requires 
recombination into the VSG expression sites (ESs), which are 
found at the telomeres of some megabase and intermediate 
chromosomes. The number of ESs in the T. brucei genome is 
still being determined, but may be as high as 20 [6]. An ES 
normally contains a single VSG (invariably most proximal to 
the telomere), a number of expression site–associated genes 
(ESAGs) and an array of 70-bp repeats upstream of the VSG 
(Figure 2). Unusually for protein-coding genes, transcription 
of the ESs is driven by RNA Polymerase (Pol) I [7], which is 
normally reserved for expression of rRNA genes. Moreover, 
a single promoter upstream of the ESAGs directs expression 
of the ES, meaning that a multigene primary transcript 
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is synthesised from which individual mature mRNAs are 
generated by trans-splicing and polyadenylation. Given this 
division of the VSGs between the ESs and silent loci, how does 
T. brucei antigenic variation occur? 
The predominant mechanism appears to be gene 
conversions that occur throughout a T. brucei infection, 
gradually feeding novel VSGs from the silent loci into the ES 
(Figure 2). Several factors that mediate this process have been 
described [8], suggesting that it is catalysed by homologous 
recombination, a DNA repair mechanism that is critical in all 
organisms to maintain genome integrity and ensure efficient 
DNA replication. In fact, the patterns of gene activation by 
recombination appear to be hierarchical in pathogens. In 
T. brucei, gene conversion activates telomeric VSGs earliest 
in an infection (Figure 1), with array VSGs and then VSG 
pseudogenes being progressively less efficiently recombined 
[4,9]. Precisely what factors dictate this hierarchy are not yet 
known, but the gene conversion of pseudogenes is segmental, 
often involving multiple genes, and relies on recombination 
in the poorly conserved VSG open reading frame sequences, 
rather than more conserved flank sequences (such as 
70-bp repeats). Like in A. marginale [10], this form of 
recombination may yield increasingly complex mosaic VSGs, 
potentially yielding a repertoire of VSG coats beyond the 
coding capacity of the genome. 
The other route for antigenic variation is transcriptional 
switching between the VSGs that occupy the ESs (Figure 
2). It remains unclear why T. brucei has evolved multiple 
ESs, since other organisms (such as B. hermsii, A. marginale, 
and Neisseria sp.) that rely on gene conversion for antigenic 
variation can function with a single antigen expression site. 
One hypothesis is that sequence differences in the ESAGs 
between ESs allows T. brucei to express subtly different gene 
products to match differing facets of the various mammals 
that they infect [11]. A second hypothesis suggests that 
expansion of the ES number provided multiple silent loci 
in which mosaic VSGs can be built during an infection [2]. 
When, and how frequently, transcriptional switching occurs 
during an infection might shed light on this, but the question 
has not been clearly answered [9].  In the former hypothesis, 
switching at the start of an infection would be needed, but 
would be counterproductive late in an infection, whereas 
the latter hypothesis would warrant continuous transcription 
switching throughout an infection (Figure 2). Irrespective 
of this, the existence of multiple ESs means that T. brucei has 
evolved a mechanism (or mechanisms) to ensure singular 
ES expression and that allows the cell to switch this control 
during growth. Until recently, the factors that mediate this 
have been mysterious, but a report in this issue of PLoS Biology 
by Figueiredo et al. [12] has cast some light in the darkness. 
Transcriptional Control of VSG Expression in T. brucei
To understand pathogen transcriptional switching, two 
questions must be answered. First, how does the cell select 
only one gene out of many for expression? Second, how does 
the cell switch expression from one gene to another? The first 
question has resonance beyond simply antigenic variation, 
since many organisms selectively activate a single gene 
from a gene family, a process that has been termed allelic 
exclusion [13]. One striking example is found in mammals, 
where a single odorant receptor gene from a family of >1,000 
is expressed in a given olfactory neuron [14]. A number 
of models have been considered for these questions in T. 
brucei, including the stochastic establishment and spread of 
transcriptionally repressive chromatin from the telomeres 
and selective localisation of a novel modified base (β-D-
glucosyl(hydroxymethyl)uracil) in the silent ESs. While these 
models cannot yet be discounted, an elegant explanation 
doi:10.1371/journal.pbio.0060185.g001 
Figure 1. VSG Switching Hierarchy in T. brucei 
The graph is adapted from [9] and shows the numbers of T. brucei cells (parasitaemia) measured in a cow for up to 70 days post-infection (this 
measurement is depicted by inversely plotting the prepatent period, in days, that a 0.2-ml inoculum of cattle blood achieves a parasitaemia of 1 
× 108.1 trypanosomes ml−1 units in an immunosuppressed mouse). Below the graph is a depiction of VSG gene activation timing (see Figure 2 for 
details of the switch mechanisms). During VSG switches driven by recombination, silent VSGs at a telomere are, in general, activated more frequently 
that subtelomeric array VSGs, which are activated more frequently than VSG pseudogenes (pseudo). It is unclear (indicated by a question mark) if 
transcriptional switches between VSG bloodstream expression sites (BES) occur predominantly at the start of an infection or continue throughout.  PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 1388 July 2008  |  Volume 6  |  Issue 7  |  e185
for singular ES transcription came from work by Navarro 
and Gull [15], who described a unique subnuclear site for ES 
transcription, termed the expression site body (ESB). The 
ESB was observed by showing that nascent transcripts from 
the active ES, and the associated RNA Pol I, localise to an area 
of the nucleus that is distinct from the nucleolus [15], while 
silent ESs appear to be spread throughout the nucleoplasm 
[16]. This leads to a model whereby the ESB represents a 
subnuclear ES activation site, accommodating a single ES 
[13,15]. This model may be compatible with suggestions by 
other workers that the control of ES expression is dictated 
by localisation of RNA elongation and processing factors to 
the single active site [17], which takes account of the fact that 
the silent ESs are actually partially transcribed, generating 
some transcripts from the region around the promoter. As 
attractive as this model is, much remains to be understood. 
For instance, what is the nature of the ESB, and how is its 
function regulated? Is the ESB sufficient to explain silencing 
of the other ESs? What relationship does it have to the process 
of transcriptional switching? The work of Figueiredo et al. [12] 
allows us to begin addressing at least some of these questions.
Epigenetic Functions of Dot1-Mediated Histone 
Methylation in T. brucei
Postranslational modification (PTM) of histones is used by 
cells to modulate chromatin compaction and structure, which 
can have profound effects on gene transcription, DNA repair 
and DNA replication. Significant progress has been made 
in mapping methylation and acetylation of trypanosomatid 
histones [18], which mainly appear to affect the flexible 
histone tails. One exception is methylation of lysine (K) 76 
on T. brucei histone H3, which affects the globular core [18]. 
This PTM is equivalent to H3K79 methylation in the yeast 
Saccharomyces cerevisiae and in mammals, which is catalysed by 
the methyltransferase Dot1 (Disruptor of telomeric silencing 
1) and affects 90% of H3s [19–22]. The activity of Dot1 is 
itself regulated by a further modification, ubiquitination of 
histone H2B on K123 in yeast [23] and K120 in mammals 
[24]. Methylation of histone lysines can have differing 
effects depending on whether mono-, di- or trimethylation is 
induced [25,26]. However, this appears not to be the case for 
yeast H3K79 methylation. Most yeast H3K79 is trimethylated 
(me3), but Dot1 appears not be a processive enzyme, 
meaning that H3K79me1 and H3K79me2 are also found in 
chromatin and have been shown to act functionally in the 
same manner as H3K79me3 [27]. 
The purpose of Dot1-mediated H3 methylation is still being 
unravelled, but it appears to provide two functions (Figure 
3): recruitment of some factors and the repulsion of others. 
Several protein domains have been described that can bind 
methylated lysines, but only the cell cycle checkpoint adaptor 
Rad9 (53BP1 in mammals) has been shown to recognise 
H3K79 [28–30]. This recruitment suggests that H3K79 
methylation has a role in controlling the cellular response to 
DNA damage by various genotoxic agents [31,32]. Repulsion 
of protein binding by H3K79 has been associated with 
transcription status in yeast, mediated through Sir proteins 
(Sir2, Sir3, and Sir4) [20,21]. Dot1 mutants in S. cerevisiae 
display reduced silencing of telomeric genes, the mating type 
locus and rDNA array. These phenotypes can be explained by 
doi:10.1371/journal.pbio.0060185.g002
Figure 2 Mechanisms of VSG Switching during Antigenic Variation in T. brucei 
The VSG gene expressed prior to a switch (indicated by a blue box) is transcribed from an expression site (ES) that is found at the telomere (vertical 
black line) of a chromosome (horizontal black line); active transcription of the ES is indicated by a dotted arrow, ESAGs are depicted by black boxes, 
and 70-bp repeat sequence is shown as a hatched box. Gene conversion to generate a VSG switch can occur by copying a silent VSG (red box) from 
a subtelomeric array into the ES, replacing the resident VSG; the amount of sequence copied during gene conversion is illustrated, and normally 
encompasses the VSG ORF and extends upstream to the 70-bp repeats. The silent VSG donor can also be telomeric (either in a mini chromosome or 
in an inactive ES); here, the downstream limit of conversion can extend to the telomere repeats, while the upstream limit can either be in the 70-bp 
repeats or the ESAGs (if the donor is in an ES). Segmental VSG conversion involves the copying of sequence from multiple, normally nonfunctional 
VSGs (pink, red, or green boxes) to generate a novel mosaic VSG in the ES. In transcriptional VSG switching, recombination appears not to be involved; 
instead, limited transcription at a silent VSG ES (indicated by a small arrow) becomes activated to generate fully active transcription, while the 
previously active ES is silenced. PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 1389 July 2008  |  Volume 6  |  Issue 7  |  e185
a model [21] that suggests H3K79 methylation is associated 
with active chromatin, and in its absence, Sir proteins spread 
from the limited regions in which they are normally found 
(e.g., telomeres), diminishing heterochromatin-mediated 
silencing. Similar associations between H3K79 methylation 
and transcription status are being made in mammals, though 
these may not involve Sir regulation [33,34].
Analysis of Dot1 function in T. brucei by G. Cross and 
colleagues suggests that these parasites have undergone 
an intriguing elaboration in the function of the 
methyltransferase, and that this activity can affect antigenic 
variation [12]. T. brucei is distinct from yeast and mammals 
in possessing two Dot1 homologues, named DOT1A and 
DOT1B [35], which appear to have arisen by an ancient 
duplication. Interestingly, the proteins have distinct activities, 
with DOT1A and DOT1B catalysing H3K76 dimethylation 
and trimethylation, respectively. The different forms of 
methylation may provide different cellular functions, since 
DOT1A mutants are lethal, while DOT1B mutants are viable 
[27]. Moreover, H3K76me2 is undetectable by antibodies 
during the G1 or G2 phases of the cell cycle but appears 
during mitosis, whereas H3K76me3 is constitutive. Despite 
these differences, each methylation mark has some influence 
on cell cycle progression, since DOT1B mutants in tsetse 
stage trypanosomes display aberrant DNA content following 
cell division and bloodstream stage mutants appear unable 
to differentiate to the tsetse stage, whereas RNA interference 
of DOT1A causes unprecedented generation of haploid cells 
during mitosis [35]. These phenotypes may be consistent with 
checkpoint functions of H3K76 methylation. 
Initially, no evidence could be found that T. brucei DOT1B 
contributed to VSG expression regulation [34]. However, 
more careful quantitative RT-PCR analysis (Figueiredo et al, 
[12]) reveals that DOT1B mutants display a ~10-fold increase 
in the abundance of VSG mRNAs originating from the 
silent ESs, suggesting partial de-repression of ES silencing. 
ES de-repression of a similar magnitude is also observed 
following RNAi of TbISWI, a SWI2/SNF2-related chromatin-
remodelling protein [36]. However, the effects differ, because 
ES de-repression following TbISWI mutation is limited to the 
promoter-proximal regions of the ESs, whereas de-repression 
in DOT1 mutants allowed transcription of the whole ESs. By 
inserting distinct antibiotic resistance markers into an active 
and silent ES, and using double antibiotic selection to screen 
for cells undergoing VSG transcriptional switching, it was 
shown that in DOT1B mutants, the transition from expressing 
one VSG to another is substantially delayed, with cells having 
mixed VSG coats detectable for many generations. Previous 
work has used a similar selection scheme to try to trap 
putative ES switch intermediates in wild-type cells [37], and 
this demonstrated that simultaneous transcription of two ESs 
is a highly unstable state. In fact, such cells appear to survive 
the antibiotic pressure by rapidly switching transcription 
between the two ES, which are found in close proximity in the 
nucleus. In addition, it appears to be impossible to trap cells 
that have similarly activated three ESs [38], suggesting that ES 
transcriptional switching is a coordinated process involving 
two ES. A question that arises, therefore, is have Figueiredo 
and colleagues identified, in DOT1B, a factor that mediates 
such switching?
Epigenetic Gene Regulation and Antigenic Variation
The precise role of DOT1B and DOT1A in T. brucei remain 
to be defined, meaning a coherent picture of transcriptional 
VSG switching is currently beyond reach. In fact, either of 
the potentially divergent functions of Dot1 in repulsion and 
recruitment of other proteins (see above) could explain the 
findings of Figueiredo et al. It is possible that H3K76me3 
acts as a marker of active transcription, including the active 
ES, and dilution of this mark in the absence of DOT1B 
allows silencing factors to move from the silent ESs, gradually 
causing their derepression [20]. This might then activate 
the switching process. If so, it is unlikely that this is mediated 
through Sir, as in yeast, because mutation of a nuclear 
T. brucei Sir2 homologue does not appear to influence 
ES transcriptional status during switching [39]. It is also 
perplexing that the rate of switching appears unaltered in 
DOT1B mutants. Moreover, only a single ESB is visible in the 
DOT1B ES double expresser, whereas two extranucleolar 
sites of ES transcription are found in such putative switch 
intermediates in wild-type cells [37]. It will be important 
to localise the subnuclear region of ES transcription in the 
DOT1B mutants. The other potential explanation for the 
DOT1B ES phenotypes may lie in DNA damage signalling, 
suggesting that H3K76me3 acts in binding of checkpoint 
factors such as Rad9/53BP1 . Little work has been done in 
this area in T. brucei, although the DNA content variations 
seen in both DOT1A and DOT1B mutants are compatible 
with a role in controlling cell cycle progression. In addition, it 
is interesting that previous work has shown that the induction 
of genotoxic damage and replication stalling can induce 
de-repression of ES silencing (as well as other loci) [40], 
potentially hinting at a link with DNA repair.
It is worth considering if the DOT1B study will have 
relevance for antigenic variation in other cells. Considerable 
work is now being done to examine the mechanisms of 
doi:10.1371/journal.pbio.0060185.g003
Figure 3. Functions of Dot1-Mediated Histone H3 Methylation 
Two models for the role of Dot1-mediated methylation of histone H3 
are diagrammed, comparing a Dot1 mutant (ΔDot1) and a wild-type 
cell. The repulsion model is derived from [21]. Methylation of histone 
H3 is indicated by “me”, and the level of transcription of a chromosome 
(black line) is indicated by a shaded gray bar (a thick bar indicates active 
transcription, a thin bar indicates silenced transcription). Silencing 
factors (such as Sir proteins in yeast; light blue circles) are indicated 
localised to the telomere (vertical line) in wild-type cells, being excluded 
from elsewhere by H3K79 methylation. Mutation of Dot1 removes 
H3K79 methylation, de-repressing transcription of the telomeric region. 
The recruitment model is based on [32], and shows the same region of 
chromosome after suffering a DNA double-strand break (gap in the line). 
Here, histone H3K79 methylation recruits a checkpoint signalling factor 
(Rad9 in yeast; dark blue circle), and in the absence of histone H3K79 
methylation processing of the DNA break to yield single stranded DNA is 
increased, amplifying the DNA damage signalling cascade.PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 1390 July 2008  |  Volume 6  |  Issue 7  |  e185
antigenic variation in P. falciparum, which is mediated by 
transcriptional switches between var genes. Here, chromatin 
modifications are associated with var gene transcriptional 
status [41,42], and it has been postulated that singular 
var gene expression is achieved through a unique site for 
transcription, akin to the ESB in T. brucei [3,43]. Though 
this may be true, the underlying details appear distinct in the 
two parasites. In P. falciparum, the inactive var genes cluster 
at the nuclear periphery rather than being dispersed in the 
nucleoplasm, and the chromosome containing the single 
active var gene that escapes silencing moves from this cluster 
but remains at the periphery [44,45]. In contrast, there is no 
evidence for clustering of silent VSG ESs or their positioning 
at the nuclear periphery in bloodstream-stage T. brucei [36], 
and the active ESB appears to be in the nucleoplasm [46]. 
Furthermore, deacetylation of histone H4 by Sir2 is an 
important determinant of var gene inactivation, with this 
epigenetic mark spreading considerably further from the P. 
falciparum telomere than is seen in yeast [45,47]. In contrast 
(as already mentioned), T. brucei SIR2 appears to have no 
role in ES silencing, and the domain of telomere-mediated 
transcriptional repression appears substantially more limited 
[38]. In conclusion, therefore, epigenetic strategies are 
now being recognised as important mediators of antigenic 
variation, though most likely T. brucei and P. falciparum have 
arrived at this commonality through convergent evolution. 
Antigenic variation represents only one route towards 
phenotypic variation in biology, and studies such as those 
discussed here will continue to enhance our understanding 
of how epigenetics can influence phenotypic change. ◼
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